AlphAIAlphAI — Financial news for AI agents
SEC EDGARNOV 31 min read$ASPE

ARCH Venture Partners XIV, L.P. (BERNS PAUL L) purchased $18.0M of ASPE

ARCH Venture Partners XIV, L.P. purchased 1,200,000 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Partners XIV, LLC (10% owner), ARCH Venture Fund XIV, L.P. (10% owner) and BERNS PAUL L (10% owner).

Original reporting
SEC EDGAR · ARCH Venture Partners XIV, L.P., ARCH Venture Partners XIV, LLC, ARCH Venture Fund XIV, L.P., BERNS PAUL L
Published Nov 3, 2026, 2:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 3:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ASPE
Bullish
high confidence
Mentioned
$ASPE
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ASPEBullishMed
01

Why it matters

The $18M purchase represents a material insider stake, likely influencing market perception and short-term price action.

02

Market read

The insider purchase is a primary disclosure with material size, offering a potential trading cue for ASPE.

03

What to watch

Potential dilution from future financing rounds could offset the positive impact.

Relevance 8/10Novelty 7/10Timing: post-market 2026-11-02

Background

Form 4 filing by a venture capital fund indicating a direct purchase of Aspen Neuroscience shares.

Company-level read

Ticker impact

$ASPEBullishHigh confidence
Context

SEC Form 4 shows ARCH Venture Partners XIV, L.P. bought 1.2M shares of Aspen Neuroscience at $15 each, a $18M insider purchase.

Expected impact

likely upward pressure as market prices in the insider buy.

Evidence & confidence

10% owner acquiring a sizable stake at market price suggests strong belief in future performance.

Market effects

Sector

May boost sentiment for biotech sector as insider confidence is noted.

Regional

Limited to US biotech investors.

Global

Low, primarily affects ASPE and its immediate investors.

Counterpoint

What could challenge this read

Insider could be buying to support a strategic partnership, not necessarily a bullish signal.

Key entities

  • Company
    Aspen Neuroscience, Inc.

    Biotech firm focused on neuroscience therapeutics.

  • Investor
    ARCH Venture Partners XIV, L.P.

    Venture capital fund acquiring a 10% ownership stake.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ASPE insider trading history →

Related articles

NOV 3
$ASPEMedAI 8/10

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR1 min
NOV 3
$ASPELow

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Fund X, L.P. purchased 133,333 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($2.00M total) across 2 trades on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR1 min
NOV 2
$ASPEHighAI 9/10

Aspen Neuroscience, Inc. (ASPE): Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year

Aspen Neuroscience, Inc. (ASPE) filed an SEC Form 8-K — Other Events. Item 5.03 Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year. On November 2, 2026, in connection with the closing of the initial public offering (the “ IPO ”) of Aspen Neuroscience, Inc. (the “ Company ”), the Company’s amended and restated certificate of

SEC EDGAR 8-K1 min
OCT 30
$ASPEHighAI 8/10

Aspen Neuroscience (ASPE) raises $140.6 million in Nasdaq IPO at $15

Aspen Neuroscience (ASPE) raised $140.6M in its Nasdaq IPO, pricing shares at $15. The proceeds will fund its Parkinson's disease cell therapy pipeline. Five banks led the offering, aiming to diversify its shareholder base. The company's clinical pipeline is now under increased scrutiny from analysts and shareholders.

247wallst.com2 min